GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology. By addressing the underlying causes of diseases rather than merely alleviating symptoms, GRI Bio aims to meet critical unmet medical needs with its transformative treatment options. The company has a strong pipeline of product candidates and actively engages in strategic collaborations to bolster its research initiatives. Positioned at the leading edge of the rapidly expanding microbiome therapeutics market, GRI Bio is dedicated to enhancing patient outcomes and has the potential to make significant contributions to the future of healthcare.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-10.93M |
| Operating Margin | 0.00% |
| Return on Equity | -185.70% |
| Return on Assets | -88.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.65 |
| Price-to-Book | 0.23 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.77M |
| Float | $1.77M |
| % Insiders | 0.46% |
| % Institutions | 2.80% |
Volatility is currently contracting
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026.
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in combination
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GRI and any ticker you trade — then tracks every position and per-strategy win rate.
